Syros Pharmaceuticals Company Insiders

Syros Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.5988) % which means that it has lost $0.5988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7696) %, meaning that it created substantial loss on money invested by shareholders. Syros Pharmaceuticals' management efficiency ratios could be used to measure how well Syros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Syros Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.27 in 2024, whereas Total Assets are likely to drop slightly above 147.5 M in 2024. Common Stock Shares Outstanding is likely to gain to about 29.7 M in 2024, whereas Net Loss is likely to drop (89.4 M) in 2024.

Syros Pharmaceuticals Workforce Comparison

Syros Pharmaceuticals Insider Trading

Syros Pharmaceuticals Notable Stakeholders

The success or failure of an entity such as Syros Pharmaceuticals often depends on how effective the management is. Syros Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Syros management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Syros management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Syros Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syros Pharmaceuticals. Check Syros Pharmaceuticals' Beneish M Score to see the likelihood of Syros Pharmaceuticals' management manipulating its earnings.

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.